Today Atlas Antibodies, based in Stockholm, Sweden, will be releasing another over 4,000 new Triple A Polyclonals. The new release brings the catalog to over 21,000 research antibodies, all presented on The Human Protein Atlas portal (www.proteinatlas.org) and over 21,000 PrEST Antigens.

All 17,000 Triple A Polyclonals recommended for immunohistochemistry (IHC) are presented with 500 images from different healthy and cancerous tissues on the Human Tissue Atlas, a cornerstone of The Human Protein Atlas.

In this new release, a large number of products are validated in ICC-IF and presented on the new Cell Atlas, which was launched in December 2016. These products are supported with confocal microscopy images with sub-cellular annotation into 32 different sub-cellular compartments and structures.

”This release expands our catalog by over 8,000 products and brings us even closer to our goal of covering the complete human proteome of 20,000 protein-coding genes with highly validated antibodies”, says Dr Marianne Hansson, CEO of Atlas Antibodies. “Our product catalog consists of antibodies and labelled and unlabeled protein fragments for both qualitative and quantitative analysis of human proteins. With more than 60,000 products, over 85% of all human proteins are currently covered.”

Atlas Antibodies Advanced Polyclonal antibodies (Triple A Polyclonals) are designed using a proprietary software to select the most suitable antigen for a given target protein. Combined with a unique antibody purification process, using the recombinant antigen as affinity ligand, polyclonal antibodies with the very highest level of specificity, reproducibility and versatility are supplied giving the products their Advanced status.

The 17,000 antibodies validated in IHC are available on the Tissue Atlas, presenting a complete map of protein expression in all major organs and tissues in the human body. In this launch, antibodies with product data from a number of new tissues never displayed before are included, such as eye including retina, lactating breast, full sections of adrenal gland and new sections of the brain.

The 10,000 antibodies validated in ICC-IF are presented on the newly released Cell Atlas, supplied with high resolution confocal microscopy images and mapped on a single-cell level to 32 subcellular structures, from organelles such as nucleus, golgi and mitochondria to sub-structures such as nuclear bodies, cytokinetic bridges and rods and rings.

Many antibodies are validated in both IHC and ICC-IF and are presented on both the Tissue and the Cell Atlas. The results of using Triple A Polyclonals in IHC, ICC-IF and WB are presented on Atlas Antibodies’ website and online store at atlasantibodies.com.

PrEST Antigens are the recombinant protein fragments used as immunogens in the generation of Triple A Polyclonals. They can be used as blocking agents or positive assay controls together with the corresponding antibody.

Atlas Antibodies manufactures and sells advanced reagents for human protein research. The company was founded in 2006 by researchers at the Royal Institute of Technology (KTH) in Stockholm and the Rudbeck Laboratory, Uppsala University in Uppsala to handle the production, marketing and sales of the antibodies and PrEST Antigens developed and validated by the Human Protein Atlas Project. Today the company offers four product lines: Triple A Polyclonals, PrecisA Monoclonals, PrEST Antigens and QPrESTs. QPrESTs are mass spectrometry standards for absolute quantification of proteins.

The company takes active part in antibody validation by sponsoring several validation initiatives, including the Global Biological Standards Institute (GBSI), where the company CSO is a representative of the IHC group.